Fitusiran (ALN-AT3SC)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 21:53, 28 October 2023 by Jwarner (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

siRNA therapeutic, targets antithrombin

Preliminary data

Inherited coagulopathy

  1. ATLAS-A/B: Srivastava A, Rangarajan S, Kavakli K, Klamroth R, Kenet G, Khoo L, You CW, Xu W, Malan N, Frenzel L, Bagot CN, Stasyshyn O, Chang CY, Poloskey S, Qiu Z, Andersson S, Mei B, Pipe SW. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2023 May;10(5):e322-e332. Epub 2023 Mar 29. link to original article PubMed NCT03417245